1. Home
  2. IDAI vs NCEL Comparison

IDAI vs NCEL Comparison

Compare IDAI & NCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo T Stamp Inc.

IDAI

T Stamp Inc.

HOLD

Current Price

$3.72

Market Cap

20.9M

Sector

Technology

ML Signal

HOLD

NCEL

NewcelX Ltd. Ordinary Shares

N/A

Current Price

$2.48

Market Cap

20.7M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
IDAI
NCEL
Founded
2016
2008
Country
United States
Switzerland
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
20.9M
20.7M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
IDAI
NCEL
Price
$3.72
$2.48
Analyst Decision
Strong Buy
Analyst Count
1
0
Target Price
$12.00
N/A
AVG Volume (30 Days)
158.6K
82.3K
Earning Date
11-14-2025
12-01-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$3,727,824.00
N/A
Revenue This Year
$3.46
N/A
Revenue Next Year
$219.85
N/A
P/E Ratio
N/A
N/A
Revenue Growth
72.57
N/A
52 Week Low
$1.43
$2.91
52 Week High
$18.75
$7.64

Technical Indicators

Market Signals
Indicator
IDAI
NCEL
Relative Strength Index (RSI) 42.08 N/A
Support Level $4.00 N/A
Resistance Level $4.57 N/A
Average True Range (ATR) 0.34 0.00
MACD -0.05 0.00
Stochastic Oscillator 8.08 0.00

Price Performance

Historical Comparison
IDAI
NCEL

About IDAI T Stamp Inc.

T Stamp Inc develops and markets identity authentication software solutions for enterprise partners and peer-to-peer markets. The company is engaged in developing proprietary artificial intelligence-powered solutions; researching and leveraging biometric science, cryptography, and data mining to deliver insightful identity & trust predictions while identifying and defending against fraudulent identity attacks, protecting sensitive user information, and extending the reach of digital services through accessibility. The artificial intelligence-powered solutions segment generates revenue principally from software licenses, professional services, and recurring Software-as-a-Service ("SaaS") revenue.

About NCEL NewcelX Ltd. Ordinary Shares

NewcelX Ltd is a biotechnology company developing transformative cell-based and small-molecule therapies for neurodegenerative and metabolic diseases. The company's integrated platform combines advanced stem-cell technologies and neuroscience expertise to deliver scalable, regenerative treatments targeting conditions such as Amyotrophic Lateral Sclerosis (ALS) and Type 1 Diabetes. It has research and development operations in Ness Ziona, Israel.

Share on Social Networks: